Category: GSK
-
At a gathering of biopharma executives, a moment of wonder — and also of worry
At a gathering of biopharma executives, a moment of wonder — and also of worry Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit on Oct. 15-16, that kind of moment came when one of the top biopharmaceutical executives in the world met a toddler in a tuxedo. Read the…
-
A pharma C-suite shakeup and Trump’s deal with Pfizer
A pharma C-suite shakeup and Trump’s deal with Pfizer How will we look back on Emma Walmsley’s tenure as GSK’s CEO? Why did one of the FDA’s top drug officials call out an obscure lupus drug on LinkedIn? And will we ever stop talking about the pharma patent cliff? We discuss all that and more…
-
Pharma sours on the U.K., plus biotech M&A’s quiet roll
Pharma sours on the U.K., plus biotech M&A’s quiet roll Are pharmaceutical companies pulling their money out of the United Kingdom because of Trump? How is biotech M&A pacing this year? And what will vaccine advisors discuss at their closely watched meeting this week? We discuss all that and more on this week’s episode of…
-
STAT+: With Trump in the U.K., GSK touts $30 billion investment in U.S. over 5 years
STAT+: With Trump in the U.K., GSK touts $30 billion investment in U.S. over 5 years LONDON — The U.K.-based drugmaker GSK said early Wednesday that it planned to invest $30 billion in the U.S. over five years, an announcement timed to this week’s state visit here by President Trump. The company, which said the…
-
STAT+: ViiV expands licensing deal for its HIV drug in low-income countries
STAT+: ViiV expands licensing deal for its HIV drug in low-income countries Once again, ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, reflecting ongoing pressure to respond to criticism. Under the latest arrangement, the company is expanding a licensing agreement reached three years ago with…